Clinical Trial Update: Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor [Phase 1]

View source ↗

Summary

Phase 1 safety and pharmacokinetic evaluation of ASA404 with fluvoxamine in solid tumors; the trial was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• ASA404 (vadimezan)
• Fluvoxamine (fluvoxamine)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Solid Tumors | Phase 1 | Status: TERMINATED